Literature DB >> 16280666

Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.

Maria Rosaria Raspollini1, Gabriella Nesi, Gianna Baroni, Lucia Roberta Girardi, Gian Luigi Taddei.   

Abstract

Distinguishing between primary adenocarcinomas and secondary colonic adenocarcinomas of the urinary bladder is often difficult because they appear morphologically similar but invariably require different treatment strategies. The aim of the study was to define the utility of a limited immunohistochemical panel consisting of CDX-2, cytokeratins 7 (CK7) and 20 (CK20), and carcinoembryonic antigen (CEA) in differentiating primary from secondary bladder adenocarcinomas. Formalin-fixed, paraffin-embedded tissues from 8 primary bladder adenocarcinomas and 23 colorectal adenocarcinomas involving the bladder were included in the study. Statistical analysis was performed using the Fisher exact test. The majority (87.5%) of primary bladder adenocarcinomas were CDX-2 negative, and only one case of primary bladder adenocarcinoma was positive, while CDX-2 was strongly expressed in the nucleus of all cases of secondary (colonic) bladder tumor (P < 0.0005). Five cases (62.5%) of primary bladder adenocarcinoma and one case (4.3%) of secondary bladder tumor showed positive staining for CK7 (P = 0.002), whereas CK20 showed positive staining in five cases (62.5%) of primary bladder adenocarcinoma and in all the secondary bladder tumors (P = 0.012). All 23 secondary bladder tumors and 7 primary bladder adenocarcinomas (87.5%) expressed CEA (P = 0.25). These data demonstrate that a restricted immunohistochemical panel consisting of CDX-2, CK7, CK20, and CEA may be of use in differentiating primary bladder adenocarcinoma from secondary adenocarcinoma of colorectal origin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280666     DOI: 10.1097/01.pai.0000136552.44045.0f

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

Review 1.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

2.  Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.

Authors:  Minyuen Teo; Niall C Swan; Ray S McDermott
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

3.  Metastatic Small Intestinal Cancer of the Urinary Bladder.

Authors:  Teppei Morikawa; Akiteru Goto; Hiroaki Nishimatsu; Masashi Fukayama
Journal:  Case Rep Oncol       Date:  2010-09-14

4.  Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature.

Authors:  Xing Xiong; Linghua Jia; Jingen Wang
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

Review 5.  Adenocarcinoma of the urinary bladder.

Authors:  Vipulkumar Dadhania; Bogdan Czerniak; Charles C Guo
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

6.  Immunohistochemical features of the gastrointestinal tract tumors.

Authors:  Hannah H Wong; Peiguo Chu
Journal:  J Gastrointest Oncol       Date:  2012-09

7.  Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge.

Authors:  Somak Roy; Matthew A Smith; Kathy M Cieply; Marie B Acquafondata; Anil V Parwani
Journal:  Diagn Pathol       Date:  2012-11-02       Impact factor: 2.644

Review 8.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.